Health care stocks were leaning lower premarket Monday with the Health Care Select Sector SPDR Fund (XLV) declining by 0.1% and the iShares Biotechnology ETF (IBB) down 0.3% recently.
KalVista Pharmaceuticals (KALV) shares were up more than 17% after the company said the US Food and Drug Administration approved its drug Ekterly, which is intended for treating acute attacks of hereditary angioedema in patients aged 12 and above.
Jasper Therapeutics (JSPR) shares were declining by more than 66% after the company said it is shutting down its asthma trial after discovering a faulty batch of its experimental drug was used to treat individuals who were enrolled in a trial evaluating briquilimab.
Lenz Therapeutics (LENZ) shares were up nearly 0.1% after the company and Laboratoires Thea said they signed an exclusive licensing and commercialization agreement to market LNZ100, Lenz's investigational eye drop for presbyopia, in Canada.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。